A pilot double-blind randomized placebo-controlled study of molsidomine 16 mg once-a-day in patients suffering from stable angina pectoris: Correlation between efficacy and over time plasma concentrations

European Journal of Clinical Pharmacology

Volumn 59, Issue 3, 2003, Pages 227-232

  Messin, Roger ^a   Fenyvesi, Tamas ^b   Carreer Bruhwyler, Fabienne ^c   Crommen, Jacques ^d   Chiap, Patrice ^d   Hubert, Philippe ^d   Dubois, Claude ^a   Famaey, Jean Pierre ^a   Géczy, Joseph ^a  

^a Therabel Pharma Belgium   (Belgium)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^c Squarepoint Pointcarre SPRL   (Belgium)

^d UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Exercise testing; Molsidomine; Stable angina pectoris

Indexed keywords

DRUG METABOLITE; LINSIDOMINE; MOLSIDOMINE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MALE; PHARMACODYNAMICS; PRIORITY JOURNAL; ST SEGMENT DEPRESSION;

AGED; ANGINA PECTORIS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLSIDOMINE; NITRIC OXIDE DONORS; PILOT PROJECTS;

EID: 0042664011     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0597-z     Document Type: Article

References (19)

1. Hug J, Hasenfuss G, Wollschlager H, Just HJ, Bonzel T (1994) Coronary dilatation after intracoronary administration of SIN-1 and intravenous molsidomine administration. Med Klin 89[Suppl 2]:34-37
2. Munzel T, Kurz S, Heitzer T, Luhmann C, Just H (1994) Effects of intravenous administration of nitroglycerin and SIN-1 or molsidomine on epicardial arterial diameter in patients with stable coronary heart disease. Med Klin 89[Suppl 2]:38-41
3. Rosenkranz B, Winkelmann BR, Parnham MJ (1996) Clinical pharmacokinetics of molsidomine. Clin Pharmacokinet 30:372-384
4. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G (1987) Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 84:9265-9269
5. Vanhoutte PM (1989) Molsidomine is a donor of EDRF. J Cardiovasc Pharmacol 14[Suppl 11]:S139-S140
6. Feelisch M, Ostrowski J, Noack E (1989) On the mechanism of NO release from sydnonimines. J Cardiovasc Pharmacol 14[Suppl 11]:S13-S22
7. Ostrowski J, Gaul G, Voegele D, Brockmeier D, Resag K (1985) Pharmacokinetics of an extended-release dosage form of molsidomine in patients with coronary heart disease. Eur J Clin Pharmacol 28:611-613
8. Messin R (1985) Exercise tolerance in coronary patients: randomized trial of two-week treatment with molsidomine versus placebo. Am Heart J 109:667-669
9. Messin R, Boxho G, De Smedt J, Buntinx IM (1995) Acute and chronic effect of molsidomine extended release on exercise capacity in patients with stable angina, a double-blind crossover clinical trial versus placebo. J Cardiovasc Pharmacol 25:558-563
10. Messin R, Karpov Y, Baikova N, Bruhwyler J, Monseu MJ, Guns C, Geczy J (1998) Short- and long-term effects of molsidomine retard and molsidomine nonretard on exercise capacity and clinical status in patients with stable angina: a multicenter randomized double-blind crossover placebo-controlled trial. J Cardiovasc Pharmacol 31:271-276
11. Rietbrock S, Keller-Stanislawski B, Thurmann P, Brockmeier D (1992) Pharmacokinetic profile of a novel slow release preparation of molsidomine. Eur J Clin Pharmacol 43:273-276
12. Conte U, Maggi L (1996) Modulation of the dissolution profiles from Geomatrix multi-layer matrix tablets containing drugs of different solubility. Biomaterials 17:889-896
13. Maggi L, Bruni R, Conte U (2000) High molecular weight polyethylene oxides (PEOs) as an alternative to HPMC in controlled release dosage forms. Int J Pharm 195:229-238
14. Strasser R, Klepzig H, Ostrowski J, Resag K (1983) Molsidomin in coronary disease. Clinico-pharmacokinetic correlation study on the effect of oral and sublingual therapy. MMW Munch Med Wochenschr 125:156-158
15. Fach WA, Becker HJ (1984) Effect duration and dose-response relation of molsidomine in patients with coronary heart disease. Z Kardiol 73:613-622
16. Redwood DR, Rosing DR, Goldstein RE, Beiser GD, Epstein SE (1971) Importance of the design of an exercise protocol in the evaluation of patients with angina pectoris. Circulation 43:618-628
17. Streel B, Ceccato A, Peerboom C, Zimmer C, Sibenaler R, Maes P (1998) Determination of molsidomine and its active metabolite in human plasma using liquid chromatography with tandem mass spectrometric detection. J Chromatogr A 819:113-123
18. Bode-Boger SM, Boger RH, Galland A, Tsikas D, Frolich JC (1998) L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. Br J Clin Pharmacol 46:489-497
19. Clini E, Volterrani M, Pagani M, Bianchi L, Porta R, Gile' LS, Giordano A, Ambrosino N (2000) Endogenous nitric oxide in patients with chronic heart failure (CHF): relation to functional impairment and nitrate-containing therapies. Int J Cardiol 73:123-130